{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:19:52Z","timestamp":1790684392022,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"name":"Polyphor Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1093\/jac\/dky227","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T15:09:30Z","timestamp":1528297770000},"page":"2400-2404","source":"Crossref","is-referenced-by-count":53,"title":["Murepavadin activity tested against contemporary (2016\u201317) clinical isolates of XDR Pseudomonas aeruginosa"],"prefix":"10.1093","volume":"73","author":[{"given":"Helio S","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E","family":"Dale","sequence":"additional","affiliation":[{"name":"Polyphor Ltd, Hegenheimermattweg 125, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"key\n\t\t\t\t20180823025348_dky227-B1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","article-title":"Murepavadin: a new antibiotic class in the pipeline","volume":"16","author":"Martin-Loeches","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20180823025348_dky227-B2","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1073\/pnas.1419677112","article-title":"Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum","volume":"112","author":"Turner","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180823025348_dky227-B3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01747-15","article-title":"Mutant alleles of lptD increase the permeability of Pseudomonas aeruginosa and define determinants of intrinsic resistance to antibiotics","volume":"60","author":"Balibar","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky227-B4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1182749","article-title":"Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa","volume":"327","author":"Srinivas","year":"2010","journal-title":"Science"},{"key":"key\n\t\t\t\t20180823025348_dky227-B5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cbic.201200276","article-title":"Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics","volume":"13","author":"Werneburg","year":"2012","journal-title":"Chembiochem"},{"key":"key\n\t\t\t\t20180823025348_dky227-B6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20180823025348_dky227-B7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/erp.10.49","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes","volume":"10","author":"Hirsch","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key\n\t\t\t\t20180823025348_dky227-B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky227-B9","doi-asserted-by":"crossref","first-page":"e02252-16","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for Optimal Resistance Monitoring program in the United States","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky227-B10","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky227","article-title":"Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky227-B11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180823025348_dky227-B12","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eleventh Edition M07-ED11E","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"key\n\t\t\t\t20180823025348_dky227-B13","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-eighth Informational Supplement M100-ED28E","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"key\n\t\t\t\t20180823025348_dky227-B14","author":"EUCAST","year":"2018"},{"key":"key\n\t\t\t\t20180823025348_dky227-B15","volume-title":"Abstracts of the Twenty-eighth European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain","author":"Bernardini","year":"2018"},{"key":"key\n\t\t\t\t20180823025348_dky227-B16","article-title":"Evaluation of aminoglycoside and carbapenem resistance in a collection of drug-resistant Pseudomonas aeruginosa clinical isolates","author":"Holbrook","year":"2017","journal-title":"Microb Drug Resist"},{"key":"key\n\t\t\t\t20180823025348_dky227-B17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180823025348_dky227-B18","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20180823025348_dky227-B19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.diagmicrobio.2011.05.010","article-title":"Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy","volume":"71","author":"Schechner","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky227-B20","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky227-B21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.idc.2017.05.002","article-title":"Antimicrobial stewardship approaches in the intensive care unit","volume":"31","author":"Doernberg","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20180823025348_dky227-B22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkx468","article-title":"In vitro activity of ceftolozane\/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008\u201316","volume":"73","author":"Walkty","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky227-B23","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky227-B24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky227-B25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/9\/2400\/25523232\/dky227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:44:59Z","timestamp":1571445899000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/9\/2400\/5036448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,6,12]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky227","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733450378.793555363","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,6,12]]}}}